<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        20-5362-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESOPOLE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        36.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Esomeprazole magnesium Delayed Release Capsules contains a medicine called esomeprazole. This belongs to a group of medicines called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces. Esomeprazole magnesium Delayed Release Capsules is used to treat the following conditions:</p><p>Adults</p><p>&bull;&nbsp; &lsquo;Gastroesophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>&bull;&nbsp;&nbsp;&nbsp; Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;<em>Helicobacter pylori&rsquo;</em>. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Stomach ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). Esomeprazole magnesium Delayed Release Capsules can also be used to stop stomach ulcers from forming if you are taking NSAIDs.</p><p>&bull;&nbsp; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged treatment after prevention of rebleeding of ulcers with intravenous Esomeprazole magnesium Delayed Release Capsules.</p><p>&nbsp;</p><p>Adolescents aged 12 years and above</p><p>&bull;&nbsp; &lsquo;Gastroesophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>&bull;&nbsp;&nbsp;&nbsp; Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;<em>Helicobacter pylori&rsquo;</em>. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Esomeprazole magnesium Delayed Release Capsules:</strong></p><p>&bull;&nbsp; If you are allergic to esomeprazole or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp; If you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lansoprazole, rabeprazole, omeprazole).</p><p>&bull;&nbsp; If you are taking a medicine containing nelfinavir (used to treat HIV infection).</p><p>&nbsp;</p><p>Do not take Esomeprazole magnesium Delayed Release Capsules if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Esomeprazole magnesium Delayed Release Capsules.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Esomeprazole magnesium Delayed Release Capsules:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a skin reaction after treatment with a medicine similar to Esomeprazole magnesium Delayed Release Capsules that reduces stomach acid.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are due to have a specific blood test (Chromogranin A).</p><p>&nbsp;</p><p>Esomeprazole magnesium Delayed Release Capsules may hide the symptoms of other diseases. <strong>Therefore, if any of the following happen to you before you start taking Esomeprazole magnesium Delayed Release Capsules or while you are taking it, talk to your doctor straight away:</strong></p><p>&bull;&nbsp; You lose a lot of weight for no reason and have problems swallowing.</p><p>&bull;&nbsp; You get stomach pain or indigestion.</p><p>&bull;&nbsp; You begin to vomit food or blood.</p><p>&bull;&nbsp; You pass black stools (blood-stained faeces).</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have been prescribed Esomeprazole magnesium Delayed Release Capsules &ldquo;on demand&rdquo; you should contact your doctor if your symptoms continue or change in character.</p><p>&nbsp;</p><p>Taking a proton pump inhibitor like Esomeprazole magnesium Delayed Release Capsules, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>&nbsp;</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with Esomeprazole magnesium Delayed Release Capsules. Remember to also mention any other ill-effects like pain in your joints.</p><p>&nbsp;</p><p>Other medicines and Esomeprazole magnesium Delayed Release Capsules</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription. This is because Esomeprazole magnesium Delayed Release Capsules can affect the way some medicines work and some medicines can have an effect on Esomeprazole magnesium Delayed Release Capsules.</p><p>&nbsp;</p><p>Do not take Esomeprazole magnesium Delayed Release Capsules if you are taking a medicine containing nelfinavir (used to treat HIV infection).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&nbsp;</p><p>&bull;&nbsp; Atazanavir (used to treat HIV infection).</p><p>&bull;&nbsp; Clopidogrel (used to prevent blood clots).</p><p>&bull;&nbsp; Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).</p><p>&bull;&nbsp; Erlotinib (used to treat cancer).</p><p>&bull;&nbsp; Citalopram, imipramine or clomipramine (used to treat depression).</p><p>&bull;&nbsp; Diazepam (used to treat anxiety, relax muscles or in epilepsy).</p><p>&bull;&nbsp; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking Esomeprazole magnesium Delayed Release Capsules.</p><p>&bull;&nbsp;&nbsp; Medicines that are used to thin your blood, such as warfarin. Your doctor may need to monitor you when you start or stop taking Esomeprazole magnesium Delayed Release Capsules.</p><p>&bull;&nbsp; Cilostazol (used to treat intermittent claudication &ndash; a pain in your legs when you walk which is caused by an insufficient blood supply).</p><p>&bull;&nbsp; Cisapride (used for indigestion and heartburn).</p><p>&bull;&nbsp; Digoxin (used for heart problems).</p><p>&bull;&nbsp; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your Esomeprazole magnesium Delayed Release Capsules treatment.</p><p>&bull;&nbsp; Tacrolimus (organ transplantation).</p><p>&bull;&nbsp; Rifampicin (used for treatment of tuberculosis).</p><p>&bull;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum) </em>(used to treat depression).</p><p>&nbsp;</p><p>&nbsp;</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as Esomeprazole magnesium Delayed Release Capsules to treat ulcers caused by <em>Helicobacter pylori </em>infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p>&nbsp;</p><p>&nbsp;</p><p>Esomeprazole magnesium Delayed Release Capsules with food and drink</p><p>You can take your Capsules with food or on an empty stomach.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will decide whether you can take Esomeprazole magnesium Delayed Release Capsules during this time. It is not known if Esomeprazole magnesium Delayed Release Capsules passes into breast milk. Therefore, you should not take Esomeprazole magnesium Delayed Release Capsules if you are breastfeeding.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Esomeprazole magnesium Delayed Release Capsules is not likely to affect you being able to drive or use any tools or machines. However, side effects such as dizziness and blurred vision may uncommonly or rarely occur (see section 4). If affected, you should not drive or use machines.</p><p>&nbsp;</p><p>Esomeprazole magnesium Delayed Release Capsules contains sucrose</p><p>Esomeprazole magnesium Delayed Release Capsules contains sugar spheres which contain sucrose, a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&bull;&nbsp;&nbsp; If you are taking this medicine for a long time, your doctor will want to monitor you (particularly if you are taking it for more than a year).</p><p>&bull;&nbsp;&nbsp; If your doctor has told you to take this medicine as and when you need it, tell your doctor if your symptoms change.</p><p>&nbsp;</p><p>How much to take</p><p>&bull;&nbsp; Your doctor will tell you how many capsules to take and how long to take them for. This will depend on your condition, how old you are and how well your liver works.</p><p>&bull;&nbsp; The recommended doses are given below.</p><p>Use in adults aged 18 and above</p><p><strong>To treat heartburn caused by gastroesophageal reflux disease (GERD):</strong></p><p>&bull;&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is one Esomeprazole magnesium Delayed Release Capsules 40 mg gastro-resistant capsule once a day</p><p>&nbsp;</p><p>for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>&bull;&nbsp; The recommended dose once the gullet has healed is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro-resistant capsule once a day</p><p>&nbsp;</p><p>&bull;&nbsp; If your gullet has not been damaged, the recommended dose is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro-resistant capsule each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro-resistant capsule each day.</p><p>&bull;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To treat ulcers caused by <em>Helicobacter pylori </em>infection and to stop them coming back:</strong></p><p>&bull;&nbsp;&nbsp; The recommended dose is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro- resistant capsule twice a day for one week.</p><p>&bull;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p>&nbsp;</p><p>&nbsp;</p><p>To treat stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</p><p>&bull;&nbsp; The recommended dose is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro- resistant capsule once a day for 4 to 8 weeks.</p><p>&nbsp;</p><p>To prevent stomach ulcers if you are taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</p><p>&bull;&nbsp; The recommended dose is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro- resistant capsule once a day.</p><p>To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome):</p><p>&bull;&nbsp; The recommended dose is Esomeprazole magnesium Delayed Release Capsules 40 mg twice a day.</p><p>&bull;&nbsp; Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for. The maximum dose is 80 mg twice a day.</p><p>&nbsp;</p><p>Prolonged treatment after prevention of re-bleeding of ulcers with intravenous Esomeprazole magnesium Delayed Release Capsules:</p><p>&nbsp;</p><p>&bull;&nbsp; The recommended dose is one Esomeprazole magnesium Delayed Release Capsules 40 mg capsule once a day for 4 weeks.</p><p>Use in adolescents aged 12 or above</p><p><strong>To treat heartburn caused by gastroesophageal reflux disease (GERD):</strong></p><p>&bull;&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is one Esomeprazole magnesium Delayed Release Capsules 40 mg gastro-resistant capsule once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.</p><p>&bull;&nbsp; The recommended dose once the gullet has healed is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro-resistant capsule once a day.</p><p>&bull;&nbsp; If your gullet has not been damaged, the recommended dose is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro-resistant capsule each day.</p><p>&bull;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To treat ulcers caused by <em>Helicobacter pylori </em>infection and to stop them coming back:</strong></p><p>&bull;&nbsp;&nbsp; The recommended dose is one Esomeprazole magnesium Delayed Release Capsules 20 mg gastro- resistant capsule twice a day for one week.</p><p>&bull;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p>&nbsp;</p><p>&nbsp;</p><p>Taking this medicine</p><p>&bull;&nbsp; You can take your capsules at any time of the day.</p><p>&bull;&nbsp; You can take your capsules with food or on an empty stomach.</p><p>&bull;&nbsp; Swallow your capsules whole with a drink of water. Do not chew or crush the capsules. This is because the capsules contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</p><p>&nbsp;</p><p>What to do if you have trouble swallowing the capsules</p><p>&bull;&nbsp; If you have trouble swallowing the capsules:</p><p>-&nbsp; Put them into a glass of still (non-fizzy) water. Do not use any other liquids.</p><p>-&nbsp;&nbsp; Stir until the capsules break up (the mixture will not be clear). Then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it.</p><p>&nbsp;</p><p>-&nbsp;&nbsp; To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.</p><p>&bull;&nbsp; If you cannot swallow at all, the capsule can be mixed with some water and put into a syringe. It can then be given to you through a tube directly into your stomach (&lsquo;gastric tube&rsquo;).</p><p>&nbsp;</p><p>Elderly</p><p>Dose adjustment is not required in the elderly.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you take more Esomeprazole magnesium Delayed Release Capsules than you should</p><p>If you take more Esomeprazole magnesium Delayed Release Capsules than prescribed by your doctor, talk to your doctor or pharmacist straight away.</p><p>If you forget to take Esomeprazole magnesium Delayed Release Capsules</p><p>&bull;&nbsp; If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose.</p><p>&bull;&nbsp; Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you notice any of the following serious side effects, stop taking Esomeprazole magnesium Delayed Release Capsules and contact a doctor immediately:</p><p>&bull;&nbsp;&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).</p><p>&bull;&nbsp;&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>&bull;&nbsp; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.</p><p>&nbsp;</p><p>&nbsp;</p><p>These effects are rare, and may affect up to 1 in 1,000 people. Other side effects include:</p><p><strong><u>Common </u></strong><u>(may affect up to 1 in 10 people) </u></p><p>&bull;&nbsp; Headache.</p><p>&nbsp;</p><p>&bull;&nbsp; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).</p><p>&bull;&nbsp; Feeling sick (nausea) or being sick (vomiting).</p><p>&bull;&nbsp; Benign polyps in the stomach.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Uncommon </u></strong><u>(may affect up to 1 in 100 people) </u></p><p>&bull;&nbsp; Swelling of the feet and ankles.</p><p>&bull;&nbsp; Disturbed sleep (insomnia).</p><p>&bull;&nbsp; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.</p><p>&bull;&nbsp; Spinning feeling (vertigo).</p><p>&bull;&nbsp; Dry mouth.</p><p>&bull;&nbsp; Changes in blood tests that check how the liver is working.</p><p>&bull;&nbsp; Skin rash, lumpy rash (hives) and itchy skin.</p><p>&bull;&nbsp; Fracture of the hip, wrist or spine (if Esomeprazole magnesium Delayed Release Capsules is used in high doses and over long duration).</p><p>&nbsp;</p><p><strong><u>Rare </u></strong><u>(may affect up to 1 in 1,000 people)</u></p><p>&bull;&nbsp;&nbsp; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.</p><p>&bull;&nbsp; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.</p><p>&bull;&nbsp; Feeling agitated, confused or depressed.</p><p>&bull;&nbsp; Taste changes.</p><p>&bull;&nbsp; Eyesight problems such as blurred vision.</p><p>&bull;&nbsp; Suddenly feeling wheezy or short of breath (bronchospasm).</p><p>&bull;&nbsp; An inflammation of the inside of the mouth.</p><p>&bull;&nbsp; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.</p><p>&bull;&nbsp; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.</p><p>&bull;&nbsp; Hair loss (alopecia).</p><p>&bull;&nbsp; Skin rash on exposure to sunshine.</p><p>&bull;&nbsp; Joint pains (arthralgia) or muscle pains (myalgia).</p><p>&bull;&nbsp; Generally feeling unwell and lacking energy.</p><p>&nbsp;</p><p>&bull;&nbsp; Increased sweating.</p><p><strong><u>Very rare </u></strong><u>(may affect up to 1 in 10,000 people) </u></p><p>&bull;&nbsp; Changes in blood count including agranulocytosis (lack of white blood cells)</p><p>&bull;&nbsp; Aggression.</p><p>&bull;&nbsp; Seeing, feeling or hearing things that are not there (hallucinations).</p><p>&bull;&nbsp; Severe liver problems leading to liver failure and inflammation of the brain.</p><p>&bull;&nbsp; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>&bull;&nbsp; Muscle weakness.</p><p>&bull;&nbsp; Severe kidney problems.</p><p>&bull;&nbsp; Enlarged breasts in men.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Not known </u></strong><u>(frequency cannot be estimated from the available data) </u></p><p>&bull;&nbsp;&nbsp; If you are on Esomeprazole magnesium Delayed Release Capsules for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&bull;&nbsp; Inflammation in the gut (leading to diarrhoea).</p><p>&bull;&nbsp; Rash, possibly with pain in the joints.</p><p>&nbsp;</p><p>&nbsp;</p><p>Esomeprazole magnesium Delayed Release Capsules may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a severely reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medication at this time.</p><p>&nbsp;</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong><em>&nbsp;&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>o Other GCC States:</em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Esomeprazole magnesium Delayed Release Capsules contains Esomeprazole magnesium Delayed Release Capsules 20 mg:</strong></p><p>The active substance is Esomeprazole.</p><p>Each delayed release capsule contains Esomeprazole magnesium dihydrate USP equivalent to Esomeprazole 20mg.</p><p>The other ingredients are: Sugar spheres, Hypromellose 2910, Meglumine, Poloxamer. Methyl Alcohol, Methylene chloride, Sodium lauryl sulphate, Isopropyl Alcohol, Methacrylic acid</p><p>&nbsp;</p><p>copolymer Triethyl citrate, Glyceryl monostearate, Talc, Sodium Hydroxide.</p><p>Empty hard gelatin capsule shells composition: FD &amp; C Blue1, D &amp; C Red 28, FD &amp; C Red 40 - D&nbsp; &amp; C Yellow 10 Titanium dioxide.</p><p>Esomeprazole magnesium Delayed Release Capsules 40 mg:</p><p><strong>&nbsp;</strong></p><p>The active substance is Esomeprazole.</p><p>Each delayed release capsule contains Esomeprazole magnesium dihydrate USP equivalent to Esomeprazole 40mg.</p><p>The other ingredients are: Sugar spheres, Hypromellose 2910, Meglumine, Poloxamer. Methyl Alcohol, Methylene chloride, Sodium lauryl sulphate, Isopropyl Alcohol, Methacrylic&nbsp; acid&nbsp; copolymer Triethyl citrate, Glycerol monostearate, Talc, Sodium Hydroxide.</p><p>Empty hard gelatin capsule shells composition: FD &amp; C Blue1, D &amp; C Red 28,&nbsp; FD &amp;&nbsp; C Red 40 - D &amp; C Yellow 10 Titanium dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Esomeprazole magnesium Delayed Release Capsules looks like? Esomeprazole magnesium Delayed Release Capsules 20mg

Purple colored size ‘3’ hard gelatin capsule imprinted with ‘H’ on cap and ‘72’ on Body filled with off white to pale yellow colored pellets.

Esomeprazole magnesium Delayed Release Capsules 40mg

Purple colored size ‘2’ hard gelatin capsule imprinted with ‘H’ on cap and ‘71’ on Body filled with  off white to pale yellow colored pellets.

How supplied:

Esomeprazole magnesium Delayed Release Capsules 20 Capsules are supplied in Blister pack. Box of 14 blistered Capsules (2 x 7’s).

Esomeprazole magnesium Delayed Release Capsules 40 Capsules are supplied in Blister pack. Box of 14 blistered Capsules (2 x 7’s).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer</p><p>&nbsp;</p><p>Saudi Amarox Industrial Company Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May, 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كبسولات ايسوبول ممتدة المفعول على دواء يسمى إيسوميبرازول، ينتمي إلى مجموعة من الأدوية تسمى &quot;مثبطات مضخة البروتون&quot;. إنها تعمل عن طريق تقليل كمية الحمض التي تنتجها معدتك .</p><p dir="RTL">يستخدم إيسوميبرازول المغنيسيوم كبسول ممتدة المفعول لعلاج الحالات التالية:</p><p dir="RTL"><strong>الكبار </strong></p><p dir="RTL">&bull;&nbsp; مرض الجزر المعدي المريئي( GERD) هذا هو المكان الذي يهرب فيه حامض المعدة إلى المريء (الأنبوب الذي يربط حلقك بطنك) مما يسبب الألم والالتهابات وحرقة المعدة.</p><p dir="RTL">&bull;&nbsp; تقرحات في المعدة أو الجزء العلوي من الأمعاء (الأمعاء) المصابة بالبكتيريا المسماة &quot;هيليكوباكتر بيلوري&quot;. إذا كنت تعاني من هذه الحالة ، فقد يصف طبيبك أيضًا المضادات الحيوية لعلاج العدوى والسماح للقرحة بالشفاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp; قرحة المعدة الناتجة عن الأدوية المسماة مضادات الالتهاب غير الستيروئيدية (الأدوية المضادة للالتهابات غير الستيرويدية). يمكن أيضًا استخدام كبسولات تأجيل الإفراز المغنيسيوم من Esomeprazole لمنع تكوّن قرحة المعدة إذا كنت تتناول مضادات الالتهاب غير الستيروئيدية.</p><p dir="RTL">&bull;&nbsp; الكثير من الأحماض في المعدة بسبب نمو البنكرياس (متلازمة زولينجر إليسون.)</p><p dir="RTL">&bull;&nbsp; المعالجة المطولة بعد الوقاية من التقرح الناجم عن كبسولات الإيزوميبرازول المغنيسيوم في الوريد.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>المراهقين الذين تتراوح أعمارهم بين 12 سنة وما فوق </strong></p><p dir="RTL">&bull;&nbsp; مرض الجزر المعدي المريئي( GERD). هذا هو المكان الذي يهرب فيه حامض المعدة إلى المريء (الأنبوب الذي يربط حلقك بطنك)مما يسبب الألم والالتهابات وحرقة المعدة.</p><p dir="RTL">&bull;&nbsp; تقرحات في المعدة أو الجزء العلوي من الأمعاء (الأمعاء( المصابة بالبكتيريا المسماة &quot;هيليكوباكتر بيلوري&quot;. إذا كنت تعاني من هذه الحالة ، فقد يصف طبيبك أيضًا المضادات الحيوية لعلاج العدوى والسماح للقرحة بالشفاء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستعمال ايسوبول كبسولات ممتدة المفعول : </strong>&nbsp;</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من حساسية تجاه إيسوميبرازول أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من حساسية تجاه الأدوية الأخرى المثبطة لمضخة البروتون (مثل بانتوبرازول ، لانسوبرازول ، رايبرازول ، أوميبرازول.)</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول دواء يحتوي على نلفينافير (يستخدم لعلاج عدوى فيروس العوز المناعي البشري)</p><p dir="LTR">&nbsp;</p><p dir="RTL">لا تأخذ كبسولات إيسومبرازول المغنيسيوم المؤجل إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكًدًا ، فتحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات إيسومبرازول المغنيسيوم المؤجل.</p><p dir="RTL"><strong>&nbsp;التحذيرات والاحتياطات </strong>&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp; تحدث إلى طبيبك أو الصيدلي قبل تناول كبسولات إيسوميبرازول المغنيسيوم المؤجل:</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من مشاكل حادة في الكبد.</p><p dir="RTL">&bull;&nbsp; إذا كنت تعاني من مشاكل في الكلى الحادة.</p><p dir="RTL">&bull;&nbsp; إذا كنت قد عانيت في أي وقت مضى من ردة فعل في الجلد بعد العلاج مع دواء مشابه لكبسولات إيزومبرازول المغنيسيوم الممتدة المفعول والتي تقلل من حمض المعدة.</p><p dir="RTL">&bull;&nbsp; إذا كان من المقرر إجراء فحص دم معين( Chromogranin A).</p><p dir="RTL">كبسولات المغنيسيوم المتأخر Esomeprazole قد تخفي أعراض الأمراض الأخرى. لذلك ، إذا حدث لك أي مما يلي قبل البدء في تناول كبسولات إيسوميبرازول المغنيسيوم المؤجل ، أو أثناء تناوله ، تحدث إلى طبيبك على الفور:</p><p dir="RTL">&bull;&nbsp; تفقد الكثير من وزنك دون سبب وتواجه مشاكل في البلع.</p><p dir="RTL">&bull;&nbsp; تشعر بألم في المعدة أو عسر هضم.</p><p dir="RTL">&bull;&nbsp; تبدأ بتقيؤ الطعام أو الدم.</p><p dir="RTL">&bull;&nbsp; تغير لون البراز الى الأسود (براز ملطخ بالدماء).</p><p dir="RTL">إذا كنت قد وصفت كبسولات إيسومبرازول المغنيسيوم المؤجل &quot;عند الطلب&quot; ، يجب عليك الاتصال بطبيبك إذا استمرت الأعراض أو تغيرت في شخصيتك.</p><p dir="RTL">إن تناول مثبط مضخة البروتون مثل كبسولات إيسومبرازول المغنيسيوم المؤجل ، خاصة على مدى أكثر من عام واحد ، قد يزيد بشكل كبير من خطر الاصابة بكسور في الفخذ أو الرسغ أو العمود الفقري. أخبر طبيبك إذا كان لديك مرض هشاشة العظام أو إذا كنت تتناول الستيرويدات القشرية</p><p dir="RTL">(التي يمكن أن تزيد من خطر هشاشة العظام).</p><p dir="RTL">إذا شعرت بطفح جلدي ، خاصة في المناطق المعرضة للشمس ، أخبر طبيبك في أقرب وقت ممكن ، حيث قد تحتاج إلى إيقاف علاجك باستخدام كبسولات إيسومبرازول المغنيسيوم المؤجلة. تذكر أيضًا ذكر أي آثار سيئة أخرى مثل الألم في مفاصلك.</p><p dir="RTL"><strong>أدوية أخرى وكبسولات الإيسوميبرازول المغنيسيوم المتأخر </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو تناولت مؤخرا أو قد تأخذ أي أدوية أخرى. يتضمن ذلك الأدوية التي تشتريها بدون وصفة طبية. وذلك لأن كبسولات ايسوميبرازول ممتد المفعول يمكن أن تؤثر على الطريقة التي تعمل بها بعض الأدوية ويمكن أن يكون لبعض الأدوية تأثير على كبسولات ايسوميبرازول ممتد المفعول.&nbsp;</p><p dir="RTL">لا تأخذ كبسولات إيسومبرازول المغنيسيوم إذا كنت تتناول دواء يحتوي على نلفينافير (يستخدم لعلاج عدوى فيروس العوز المناعي البشري).</p><p dir="LTR">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أياً من الأدوية التالية:</p><p dir="RTL">&bull;&nbsp; الأتَازانافير (يستخدم لعلاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">&bull;&nbsp; كلوبيدوجريل (يستخدم لمنع جلطات الدم).</p><p dir="RTL">الكيتوكونازول أو إيتراكونازول أو فوركونازول (يستخدم لعلاج الالتهابات التي تسببها الفطريات).</p><p dir="RTL">إرلوتينيب (يستخدم لعلاج السرطان).</p><p dir="RTL">&bull;&nbsp; سيتالوبرام ، إيميبرامين أو كلوميبرامين (يستخدم لعلاج الاكتئاب).</p><p dir="RTL">&bull;&nbsp; الديازيبام (يستخدم لعلاج القلق أو استرخاء العضلات أو الصرع).</p><p dir="RTL">&bull;&nbsp; الفينيتوين (يستخدم في الصرع). إذا كنت تتناول الفينيتوين ، فسوف يحتاج طبيبك إلى مراقبتك عندما تبدأ أو تتوقف عن تناول كبسولات إيسومبرازول المغنيسيوم المؤجل.</p><p dir="RTL">&bull;&nbsp; الأدوية المستخدمة لتخفيف دمك ، مثل الوارفارين. قد يحتاج طبيبك إلى مراقبتك عندما تبدأ أو تتوقف عن تناول كبسولات إيسوميبرازول المغنيسيوم المؤجل.</p><p dir="RTL">&bull;&nbsp; سيلوستازول (يستخدم لعلاج العرج المتقطع - ألم في ساقيك عندما تمشي بسبب نقص إمدادات الدم).</p><p dir="RTL">&bull;&nbsp; سيسابريد (يستخدم لعسر الهضم وحرقة في المعدة).</p><p dir="RTL">&bull;&nbsp; الديجوكسين (يستخدم لمشاكل القلب). &nbsp;</p><p dir="RTL">&bull;&nbsp; الميثوتريكسيت (دواء العلاج الكيميائي المستخدم في الجرعات العالية لعلاج السرطان( - إذا كنت تتناول جرعة عالية من الميثوتريكسيت،&nbsp; فقد يوقف طبيبك مؤقتاً علاج كبسولات الإيسوميبرازول المغنيسيوم المؤجل.</p><p dir="RTL">&bull;&nbsp; تاكروليموس &nbsp;(زرع الأعضاء). &nbsp;</p><p dir="RTL">&bull;&nbsp; ريفامبيسين (يستخدم لعلاج مرض السل). &nbsp;</p><p dir="RTL">&bull;&nbsp; نبتة سانت جون (هايبيريكم بيرفراتم )العرن المثقوب( وتعرف باسم :نبتة القديس المثقبة)(تستخدم لعلاج الاكتئاب). &nbsp;</p><p dir="RTL">إذا وصف طبيبك المضادات الحيوية أموكسيسيلين وكلاريثروميسين وكذلك كبسولات إيسوميبرازول المغنيسيوم المؤجل لإطلاق علاج القرحة الناتجة عن إصابة هيليكوباكتر بيلوري ، فمن المهم أن تخبر طبيبك عن أي أدوية أخرى تتناولها.</p><p dir="RTL"><strong>كبسولات الإيسوميبرازول المغنيسيوم مع الطعام والشراب </strong></p><p dir="RTL">يمكنك تناول الكبسولات مع الطعام أو على معدة فارغة.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة </strong></p><p dir="RTL">إذا كنت حاملاً ، او تفكري في الحمل أو تخطط لإنجاب طفل ، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. سيقرر طبيبك ما إذا كان يمكنك تناول كبسولات إيسومبرازول المغنيسيوم خلال هذا الوقت. لا يعُرف ما إذا كانت كبسولات إيسوميبرازول المغنيسيوم تنفذ إلى حليب الأم لذلك ، يجب ألا تتناول كبسولات إيسومبرازول المغنيسيوم المؤجل إذا كنت ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">من غير المحتمل أن تؤثر كبسولات إيسومبرازول المغنيسيوم على قدرتك على القيادة أو استخدام أي أدوات أو آلات. ومع ذلك ، قد تحدث آثار جانبية مثل الدوخة وعدم وضوح الرؤية بشكل غير شائع أو نادرًا ما (انظر القسم 4(. إذا تأثرت ، يجب ألا تقود أو تستخدم الآلات.</p><p dir="RTL"><strong>كبسولات إيسوميبرازول المغنيسيوم يحتوي على السكروز </strong></p><p dir="RTL">تحتوي كبسولات إيسوميبرازول المغنيسيوم المؤجل على كريات السكر التي تحتوي على السكروز ، وهو نوع من السكر. إذا أخبر طبيبك أن كان لديك تحسس اً لبعض السكريات ، فتحدث إلى طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تأخذ هذا الدواء تماما كما أخبر طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول هذا الدواء لفترة طويلة ، فسوف يرغب طبيبك في مراقبتك (خاصةً إذا كنت تتناوله لأكثر من عام).</p><p dir="RTL">&bull;&nbsp; إذا أخبرك طبيبك بتناول هذا الدواء عند الحاجة إليه ، فأخبر طبيبك إذا تغيرت الأعراض.</p><p dir="LTR">&nbsp;</p><p dir="LTR"><strong>.دائما تأخذ هذا الدواء تماما كما أخبر طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا كنت غير متأكد</strong></p><p dir="RTL">&bull;&nbsp; إذا كنت تتناول هذا الدواء لفترة طويلة ، فسوف يرغب طبيبك في مراقبتك (خاصةً إذا كنت تتناوله لأكثر من عام).</p><p dir="RTL">&bull;&nbsp; إذا أخبرك طبيبك بتناول هذا الدواء عند الحاجة إليه ، فأخبر طبيبك إذا تغيرت الأعراض.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>كم تأخذ </strong></p><p dir="RTL">&bull;&nbsp; سيخبرك طبيبك بعدد الكبسولات التي يجب أخذها والوقت الذي تستغرقه. هذا سيعتمد على حالتك ومدى عمرك ومدى عمل الكبد.</p><p dir="RTL">&bull;&nbsp; يتم إعطاء الجرعات الموصى بها أدناه.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>استخدامها في البالغين الذين تتراوح أعمارهم بين 18 وما فوق </strong></p><p dir="LTR"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لعلاج حرقة المعدة الناجمة عن مرض الجزر المعدي المريئي( </strong><strong>GERD</strong><strong>): </strong></p><p dir="RTL">&bull;&nbsp; إذا اكتشف طبيبك أن أنبوب الطعام (المريء( قد تعرض لأضرار طفيفة ، فإن الجرعة الموصى بها هي كبسولة واحدة من كبسولات</p><p dir="RTL">إيسوميبرازول المغنيسيوم 40 ملغ مرة واحدة يومياً لمدة 4 أسابيع. قد يخبرك طبيبك بتناول الجرعة نفسها لمدة 4 أسابيع أخرى إذا لم تلتئم المريء بعد.</p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها بمجرد شفاء المريء هي كبسولة واحدة من كبسولات إيسوميبرازول المغنيسيوم المتأخر 20 مرة في اليوم.</p><p dir="LTR">&nbsp;</p><p dir="RTL">&bull;&nbsp; إذا لم تتضرر المريء ، فإن الجرعة الموصى بها هي كبسولة واحدة من كبسولات إيسوميبرازول المغنيسيوم 20 ملغ كل يوم. بمجرد السيطرة على الحالة ، قد يخبرك طبيبك بتناول الدواء عند الحاجة إليه ، بحد أقصى كبسولة واحدة من كبسولات إيسومبرازول المغنيسيوم 20 ملغ كل يوم.</p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكبد ، فقد يعطيك طبيبك جرعة أقل.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>لعلاج القرحة الناتجة عن عدوى هيليكوباكتر بيلوري ولمنعهم من العودة: </strong></p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من كبسولات إيسوميبرازول المغنيسيوم 20 ميليغرام مرتين في اليوم لمدة أسبوع.</p><p dir="RTL">&bull;&nbsp; سيخبرك طبيبك أيضًا بتناول المضادات الحيوية مثل أموكسيسيلين وكلاريثروميسين.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>لعلاج قرحة المعدة التي تسببها مضادات الالتهاب غير الستيروئيدية (الأدوية المضادة للالتهابات غير الستيرويدية): &nbsp;</strong></p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من كبسولات الإيسوميبرازول المغنيسيوم 20 مرة في اليوم لمدة 4 إلى 8 أسابيع.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>لمنع قرحة المعدة إذا كنت تتناول مضادات الالتهاب غير الستيرويدية (الأدوية المضادة للالتهابات).</strong> الجرعة الموصى بها هي كبسولة واحدة من كبسولات الإيسوميبرازول المغنيسيوم 20 مرة في اليوم.</p><p dir="RTL"><strong>لعلاج الكثير من الأحماض في المعدة الناتجة عن نمو البنكرياس (متلازمة زولينجر إليسون): &nbsp;</strong></p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها هي كبسولات إيسوميبرازول المغنيسيوم 40 ملغ مرتين في اليوم.</p><p dir="RTL">&bull;&nbsp; سيقوم الطبيب بتعديل الجرعة حسب احتياجاتك وسيقرر أيضًا المدة التي تحتاجها لتناول الدواء. الجرعة القصوى هي 80 ملغ مرتين في اليوم.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>علاج مطول بعد الوقاية من إعادة نزيف القرحة بإيسوميبرازول في الوريد: </strong></p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها هي واحدة من كبسولات إيسوميبرازول المغنيسيوم 40 ملغ كبسولة مرة واحدة في اليوم لمدة 4 أسابيع.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>الاستخدام في علاج المراهقين الذين تتراوح أعمارهم بين </strong><strong>12</strong><strong> سنة أو أعلى لعلاج حرقة المعدة الناجمة عن مرض الجزر المعدي المريئي( </strong><strong>GERD</strong><strong>):</strong></p><p dir="RTL">&bull;&nbsp; إذا اكتشف طبيبك أن أنبوب الطعام (المريء( قد تعرض لأضرار طفيفة ، فإن الجرعة الموصى بها هي كبسولة واحدة من كبسولات</p><p dir="RTL">إيسوميبرازول المغنيسيوم 40 ملغ مرة واحدة يومياً لمدة 4 أسابيع. قد يخبرك طبيبك بتناول الجرعة نفسها لمدة 4 أسابيع أخرى إذا لم تلتئم المريء بعد.</p><p dir="RTL">الجرعة الموصى بها بمجرد شفاء المريء هي كبسولة واحدة من كبسولات الإيسوميبرازول المغنيسيوم 20 مرة في اليوم.</p><p dir="RTL">&bull;&nbsp; إذا لم يتضرر المريء ، فإن الجرعة الموصى بها هي كبسولة واحدة من كبسولات إيسوميبرازول المغنيسيوم 20 ملغ كل يوم.</p><p dir="RTL">إذا كنت تعاني من مشاكل حادة في الكبد ، فقد يعطيك طبيبك جرعة أقل.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>لعلاج القرحة الناتجة عن عدوى هيليكوباكتر بيلوري ولمنعها من العودة: </strong></p><p dir="RTL">&bull;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من كبسولات إيسوميبرازول المغنيسيوم 20 ميليغرام مرتين في اليوم لمدة أسبوع.</p><p dir="RTL">&bull;&nbsp; سيخبرك طبيبك أيضًا بتناول المضادات الحيوية مثل أموكسيسيلين وكلاريثروميسين.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>تناول هذا الدواء </strong></p><p dir="RTL">&bull;&nbsp; يمكنك تناول كبسولاتك في أي وقت من اليوم.</p><p dir="RTL">&bull;&nbsp; يمكنك تناول كبسولاتك مع الطعام أو على معدة فارغة.</p><p dir="RTL">&bull;&nbsp; ابتلع كبسولاتك بالكامل مع شرب الماء. لا تمضغ أو تسحق الكبسولات. وذلك لأن الكبسولات تحتوي على كريات مغلفة تمنع تكسير الدواء بواسطة الحامض في معدتك. من المهم عدم إتلاف الكريات.</p><p dir="RTL"><strong>ماذا تفعل إذا كنت تواجه مشكلة في ابتلاع الكبسولات </strong></p><p dir="RTL">&bull;&nbsp; إذا كنت تواجه مشكلة في ابتلاع الكبسولات:</p><p dir="RTL">-&nbsp; ضعها في كوب من الماء (غير الغازي). لا تستخدم أي سوائل أخرى.</p><p dir="RTL">-&nbsp; حرك حتى تفكك الكبسولات (لن يكون الخليط واضحًا). ثم اشرب الخليط مباشرة أو خلال 30 دقيقة. حرك الخليط دائما قبل شربه.</p><p dir="RTL">-&nbsp; للتأكد من أنك قد شربت الدواء بالكامل ، اشطفه جيًدًا بنصف كوب من الماء واشربه. تحتوي الأجزاء الصلبة على الدواء - لا تمضغها أو تسحقها.</p><p dir="RTL">&bull;&nbsp; إذا لم تستطع البلع على الإطلاق ، فيمكن خلط الكبسولة ببعض الماء ووضعها في محقنة. يمكن بعد ذلك إعطاؤها لك من خلال أنبوب مباشر إلى معدتك (&quot;أنبوب معدي). &quot;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>كبار السن </strong></p><p dir="RTL">تعديل الجرعة غير مطلوب في كبار السن.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>إذا كنت نتاولت من كبسولات إيسوميبرازول المغنيسيوم اكثر مما ينبغي </strong></p><p dir="RTL">إذا كنت تتناول أكثر من كبسولات من إيسومبرازول المغنيسيوم أكثر مما وصفه الطبيب ، فتحدث إلى طبيبك أو الصيدلي على الفور.</p><p dir="RTL"><strong>إذا نسيت تناول كبسولات إيسوميبرازول المغنيسيوم المتأخر </strong></p><p dir="RTL">&bull;&nbsp; إذا نسيت تناول جرعة ، فاخذها بمجرد تذكرها. ومع ذلك ، إذا حان وقت الجرعة التالية تقريباً ، تخطي الجرعة الفائتة.</p><p dir="RTL">&bull;&nbsp; لا تأخذ جرعة مضاعفة (جرعتين في نفس الوقت) لتعويض جرعة منسية.</p><p dir="LTR">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حصول الجميع عليها.</p><p dir="RTL"><strong>إذا لاحظت أيًا من الآثار الجانبية الخطيرة التالية ، فتوقف عن تناول كبسولات الإيسوميبرازول المغنيسيوم المؤجل والإتصال بالطبيب على الفور: </strong></p><p dir="RTL">&bull;&nbsp; صفير مفاجئ أو تورم في شفتيك أو لسانك أو حلقك أو جسمك أو طفح جلدي أو إغماء أو صعوبات في البلع (رد فعل تحسسي شديد). &nbsp;</p><p dir="RTL">&bull;&nbsp; احمرار الجلد بالبثور أو التقشير. قد يكون هناك أيضًا بثور شديدة ونزيف في الشفاه والعينين والفم والأنف والأعضاء التناسلية. يمكن أن يكون هذا</p><p dir="RTL">&quot;متلازمة ستيفنز جونسون&quot; أو &quot;تحلل البشرة السمي.&quot;</p><p dir="RTL">&bull;&nbsp; الجلد الأصفر والبول الداكن والتعب الذي يمكن أن يكون من أعراض مشاكل الكبد.</p><p dir="LTR">&nbsp;</p><p dir="RTL">هذه الآثار نادرة ، وقد تؤثر على ما يصل إلى 1 من كل 1000 شخص.</p><p dir="LTR">&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL">الآثار الجانبية الأخرى تشمل:</p><p dir="RTL"><strong>شائع</strong> (قد يؤثر على شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp; صداع الراس.</p><p dir="RTL">&bull;&nbsp; التأثيرات على المعدة أو الأمعاء: الإسهال وآلام المعدة والإمساك والرياح (انتفاخ البطن). &nbsp;</p><p dir="RTL">&bull;&nbsp; الشعور بالمرض (الغثيان)أو المرض (القيء). &nbsp;</p><p dir="RTL">&bull;&nbsp; الاورام الحميدة في المعدة.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>غير شائع </strong>(قد يؤثر على ما يصل إلى شخص من كل 100 شخص)</p><p dir="RTL">&bull;&nbsp; تورم القدمين والكاحلين.</p><p dir="RTL">&bull;&nbsp; النوم المضطرب (الأرق). &nbsp;</p><p dir="RTL">&bull;&nbsp; الدوار ، وخز المشاعر مثل &quot;المسامير والإبر&quot; ، والشعور بالنعاس.</p><p dir="RTL">&bull;&nbsp; شعور الغزل (الدوار). &nbsp;</p><p dir="RTL">&bull;&nbsp; فم جاف.</p><p dir="RTL">&bull;&nbsp; تغييرات في اختبارات الدم التي تتحقق من كيفية عمل الكبد.</p><p dir="RTL">&bull;&nbsp; طفح جلدي ، طفح جلدي متقطع (خلايا النحل) وحكة في الجلد.</p><p dir="RTL">&bull;&nbsp; كسر في مفصل الورك أو الرسغ أو العمود الفقري (إذا تم استخدام كبسولات تأخر الافراج عن المغنيسيوم في إيزوميبارازول في جرعات عالية وعلى مدى فترة طويلة). &nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>نادر</strong> (قد يؤثر على شخص واحد من كل 1000 شخص)</p><p dir="RTL">&bull;&nbsp; مشاكل في الدم مثل انخفاض عدد الخلايا البيضاء أو الصفائح الدموية. هذا يمكن أن يسبب الضعف ، كدمات أو تجعل العدوى أكثر احتمالا.</p><p dir="RTL">&bull;&nbsp; انخفاض مستويات الصوديوم في الدم. قد يتسبب هذا في الضعف ، أو المرض (التقيؤ) والتشنجات.</p><p dir="RTL">&bull;&nbsp; الشعور بالإثارة أو الخلط أو الاكتئاب.</p><p dir="RTL">&bull;&nbsp; تذوق التغييرات.</p><p dir="RTL">&bull;&nbsp; مشاكل البصر مثل عدم وضوح الرؤية.</p><p dir="RTL">&bull;&nbsp; الشعور فجأة بالوزيز أو ضيق التنفس (تشنج قصبي). &nbsp;</p><p dir="RTL">&bull;&nbsp; التهاب داخل الفم.</p><p dir="RTL">&bull;&nbsp; عدوى تسمى &quot;القلاع&quot; والتي يمكن أن تؤثر على الأمعاء وتسببها الفطريات.</p><p dir="RTL">&bull;&nbsp; مشاكل في الكبد ، بما في ذلك اليرقان الذي يمكن أن يسبب الجلد الأصفر والبول الداكن والتعب.</p><p dir="RTL">&bull;&nbsp; تساقط الشعر (الثعلبة). &nbsp;</p><p dir="RTL">&bull;&nbsp; طفح جلدي على التعرض لأشعة الشمس.</p><p dir="RTL">&bull;&nbsp; آلام المفاصل (ألم مفصلي) أو آلام في العضلات( ألم عضلي). &nbsp;</p><p dir="RTL">&bull;&nbsp; الشعور عموما بتوعك ونقص الطاقة.</p><p dir="RTL">&bull;&nbsp; زيادة التعرق.</p><p dir="RTL"><strong>نادر جدًا</strong> (قد يؤثر على ما يصل إلى شخص واحد من كل 10000 شخص)&bull; التغيرات في تعداد الدم بما في ذلك ندرة المحببات (نقص خلايا الدم البيضاء)</p><p dir="RTL">&bull;&nbsp; العدوان.</p><p dir="RTL">&bull;&nbsp; رؤية الأشياء التي ليست موجودة (الهلوسة)أو الشعور بها أو سماعها.</p><p dir="RTL">&bull;&nbsp; مشاكل الكبد الحادة التي تؤدي إلى فشل الكبد والتهاب الدماغ.</p><p dir="RTL">&bull;&nbsp; ظهور مفاجئ لطفح جلدي شديد أو تقرحات أو تقشير الجلد. قد يترافق هذا مع ارتفاع في درجة الحرارة وآلام المفاصل (حمامي عديدة الأشكال ، متلازمة ستيفنز جونسون ، انحلال البشرة السام). &nbsp;</p><p dir="RTL">ضعف العضلات.</p><p dir="RTL">&bull;&nbsp; مشاكل في الكلى الحادة.</p><p dir="RTL">&bull;&nbsp; تكبير الثديين عند الرجال.</p><p dir="RTL"><strong>غير معروف</strong> (لا يمكن تقدير التردد من البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp; إذا كنت تستخدم كبسولات إيسوميبرازول المغنيسيوم لأكثر من ثلاثة أشهر ، فمن المحتمل أن تنخفض مستويات المغنيسيوم في دمك. يمكان رؤية مستويات منخفضة من المغنيسيوم كإرهاق أو انقباضات عضالية لا إرادية أو ارتباك أو تشنجات أو دوخة أو زيادة معادل ضاربات القلاب. إذا أصابت بأي مان هذه الأعراض ، فيرجى إخبار طبيباك على الفور. يمكان أن تؤدي المستويات المنخفضة مان المغنيسيوم أيضًا إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك إجراء اختبارات دم منتظمة لمراقبة مستويات المغنيسيوم لديك.</p><p dir="RTL">&bull;&nbsp; التهاب في الأمعاء (يؤدي إلى الإسهال). &nbsp;</p><p dir="RTL">&bull;&nbsp; الطفح الجلدي ، وربما مع ألم في المفاصل.</p><p dir="LTR">&nbsp;</p><p dir="RTL">كبسولات إيساوميبرازول المغنيسيوم قاد تؤثر في حالات نادرة جادا على خلايا الدم البيضاء مما يؤدي إلى نقاص المناعة. إذا كان لديك عدوى بأعراض مثال الحمى ذات الحالة العامة شديدة الانخفاض أو الحمى مع أعراض العدوى الموضعية مثال ألام في الرقبة أو الحلق أو الفم أو صعوبات في التبول ، يجاب علياك استشارة الطبيب في أقرب وقت ممكن حتى يتسنى لك نقص خلايا الدم البيضاء (نادرة المحببات) يمكن استبعاده عن طريق فحص الدم. من المهم بالنسبة لك تقديم معلومات عن دوائك في هذا الوقت.</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية:&nbsp; </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظار التفاصيل أدناه).&nbsp;</p><p dir="RTL">بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ الكبسولات في درجة حرارة أقل من 30 درجة مئوية .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ الكبسولات في عبوتها الأصلية بعيدا عن الرطوبة .&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ايسوبول كبسولات ممتدة المفعول بعد تاريخ انتهاء الصلاحية الموجود على العبوة . تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية . استشر الصيدلي في كيفية التخلص من الأدوية التي لم تعد مطلوبة . حيث أنه من شأن هذه التدابير المساعدة على حماية البيئة .&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما تحتويه ايسوبول كبسولات ممتدة المفعول&nbsp; <strong>ايسوبول كبسولات ممتدة المفعول </strong><strong>20</strong><strong> ملغم: </strong></p><p dir="RTL">المادة الفعالة هي إيسوميبرازول<strong> </strong>.</p><p dir="RTL">تحتوي كل كبسوله من ايسوبول كبسولات ممتدة المفعول على إيسوميبرازول ماغنسيوم ثنائي الهيدرات المتوافق مع دستور الأدوية الأمريكي ما يكافئ 20 ملغم من إيسوميبرازول.&nbsp;</p><p dir="RTL">الصواغات الأخرى هي: كرات السكر ، هيبروميلوز 2910 ، ميجلومين ، بولوكسامير ، كحول ميثيلي ، كلوريد الميثيلين ، كبريتات لوريل الصوديوم ، كحول الآيزوبروبيلي ، كوبوليمر حمض الميثاكريليك ثلاثي إيثيل سيترات ، جليسيريل أحادي الإستيارات ، تالك ، هيدروكسيد الصوديوم .</p><p dir="RTL">الكبسولات الجيلاتينية الفارغة مقاس 3 ، لون الغطاء-أرجواني وجسم الكبسولة - أرجواني مطبوع علامة&quot; H &quot;على الغطاء و&quot; 72&quot; على الجسم .</p><p dir="RTL"><strong>ايسوبول كبسولات ممتدة المفعول </strong><strong>40</strong><strong> ملغم: </strong></p><p dir="RTL">المادة الفعالة هي إيسوميبرازول<strong> </strong>.</p><p dir="RTL">تحتوي كل كبسوله من ايسوبول كبسولات ممتدة المفعول على إيسوميبرازول ماغنسيوم ثنائي الهيدرات المتوافق مع دستور الأدوية الأمريكي ما يكافئ 40 ملغم من إيسوميبرازول.&nbsp;</p><p dir="RTL">الصواغات الأخرى هي: كرات السكر ، هيبروميلوز 2910 ، ميجلومين ، بولوكسامير ، كحول ميثيلي ، كلوريد الميثيلين ، كبريتات لوريل الصوديوم ، كحول الآيزوبروبيلي ، كوبوليمر حمض الميثاكريليك ثلاثي إيثيل سيترات ، جليسيريل أحادي الإستيارات ، تالك ، هيدروكسيد الصوديوم .</p><p dir="RTL">الكبسولات الجيلاتين الفارغة مقاس 2 ، لون الغطاء-أرجواني وجسم الكبسولة - أرجواني مطبوع علامة&quot; H &quot;على الغطاء و&quot; 71&quot; على الجسم .</p><p dir="LTR">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;<strong>ما هو شكل ايسوبول كبسولات ممتدة المفعول ومحتويات العلبة ؟ ايسوبول كبسولات ممتدة المفعول </strong><strong>20</strong><strong> ملغم&nbsp; </strong></p><p dir="RTL">كبسولات جيلاتينية صلبة ذات مقاس 3 بوصة ملونة مطبوع عليها &quot;H&quot; على الغطاء و&quot; 72 &quot;على الجسم مملوءة بحبيبات ذات اللون الأبيض القاتم إلى اللون الأصفر الباهت .&nbsp;</p><p dir="RTL"><strong>ايسوبول كبسولات ممتدة المفعول </strong><strong>40</strong><strong> ملغم&nbsp; </strong></p><p dir="RTL">كبسولات جيلاتينية صلبة ذات مقاس 3 بوصة ملونة مطبوع عليها &quot;H&quot; على الغطاء و&quot; 71 &quot;على الجسم مملوءة بحبيبات ذات اللون الأبيض القاتم إلى اللون الأصفر الباهت .&nbsp;</p><p dir="LTR">&nbsp;</p><p dir="RTL"><strong>توافر ايسوبول كبسولات ممتدة المفعول: </strong></p><p dir="RTL">علبة ايسوبول كبسولات ممتدة المفعول 20 ملغم تحتوي على 14 و 28 و56 كبسولة من ايسوبول كبسولات ممتدة المفعول.</p><p dir="RTL">علبة ايسوبول كبسولات ممتدة المفعول 40 ملغم تحتوي على&nbsp; 14 و 28 و 56 كبسولة من ايسوبول كبسولات ممتدة المفعول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع&nbsp; </strong></p><p dir="RTL"><strong>المصنع: </strong></p><p dir="RTL"><strong>شركة هيترو&nbsp; </strong></p><p dir="RTL"><strong>حيدر اباد &ndash; تيلانقا &ndash; الهند </strong></p><p dir="RTL">هاتف : 00918458275314&nbsp;</p><p dir="RTL"><strong>صاحب حق التسويق: </strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز - الرياض</p><p dir="RTL">المملكة العربية السعودية .&nbsp;&nbsp;&nbsp;</p><p dir="RTL">هاتف : 00966114772215&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو /2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esomeprazole Magnesium Delayed Release Capsules 40mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esomeprazole Magnesium Delayed Release Capsules 40mg 
 
Each delayed release capsule contains Esomeprazole magnesium Dihydrate USP equivalent to Esomeprazole 40mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esomeprazole magnesium Delayed Release Capsules 40mg 
Purple colored size ‘2’ hard gelatin capsule imprinted with ‘H’ on cap and ‘71’ on Body filled with off white to pale yellow colored pellets. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Esomeprazole magnesium Delayed Release Capsules 40mg</u> </strong></p><p><u>Esomeprazole Magnesium Delayed Release Capsules are indicated in adults for:</u></p><p>Gastroesophageal Reflux Disease (GERD) &ndash; treatment of erosive reflux esophagitis.</p><p>Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers.</p><p>Treatment of Zollinger Ellison Syndrome</p><p><u>Esomeprazole Magnesium Delayed Release Capsules are indicated in adolescents from the age of</u> <u>12 years for:</u></p><p>Gastroesophageal Reflux Disease (GERD)</p><p>-&nbsp;&nbsp; treatment of erosive reflux esophagitis<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology</p><p><em><u>Adults</u> </em></p><p>Gastroesophageal Reflux Disease (GERD)</p><p><u>- Treatment of erosive reflux esophagitis</u> 40 mg once daily for 4 weeks.</p><p>An additional 4 weeks treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms.</p><p><em>Prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. </em></p><p>40 mg once daily for 4 weeks after i.v. induced prevention of rebleeding of peptic ulcers.</p><p>Treatment of Zollinger Ellison Syndrome</p><p>The recommended initial dosage is Esomeprazole Magnesium Delayed Release Capsules 40 mg twice daily. The dosage should then be individually adjusted and treatment continued as long as clinically indicated. Based on the clinical data available, the majority of patients can be controlled on doses between 80 to 160 mg esomeprazole daily. With doses above 80 mg daily, the dose should be divided and given twice daily.</p><p>Special Populations</p><p>Renal impairment</p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution (see section</p><p>5.2).</p><p>Hepatic impairment</p><p>Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg Esomeprazole Magnesium Delayed Release Capsules should not be exceeded (see section 5.2).</p><p>Elderly</p><p>Dose adjustment is not required in the elderly.</p><p>Paediatric population</p><p><em><u>Adolescents from the age of 12 years</u> </em></p><p>Gastroesophageal Reflux Disease (GERD)</p><p><u>- treatment of erosive reflux esophagitis</u> 40 mg once daily for 4 weeks.</p><p>An additional 4 weeks treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to substituted benzimidazoles or to any of the excipients listed in section 6.1. 
Esomeprazole should not be used concomitantly with nelfinavir (see section 4.5). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with Esomeprazole Magnesium Delayed Release Capsules may alleviate symptoms and delay diagnosis.</p><p>Long term use</p><p>Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.</p><p>On demand treatment</p><p>Patients on on-demand treatment should be instructed to contact their physician if their symptoms change in character.</p><p>Helicobacter pylori eradication</p><p>When prescribing esomeprazole for eradication of <em>Helicobacter pylori</em>, possible drug interactions for all components in the triple therapy should be considered. Clarithromycin is a potent inhibitor of CYP3A4 and hence contraindications and interactions for clarithromycin should be considered when the triple therapy is used in patients concurrently taking other drugs metabolised via CYP3A4 such as cisapride.</p><p>Gastrointestinal infections</p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter </em>(see section 5.1).</p><p>Absorption of vitamin B12</p><p>Esomeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>Hypomagnesaemia</p><p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like esomeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>&nbsp;</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>&nbsp;</p><p>Risk of fracture</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.&nbsp;</p><p>&nbsp;</p><p>Subacute cutaneous lupus erythematosus (SCLE)</p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Esomeprazole Magnesium Delayed Release Capsules. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p>Combination with other medicinal products</p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; esomeprazole 20 mg should not be exceeded.</p><p>Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.</p><p>&nbsp;</p><p>When prescribing esomeprazole for on demand therapy, the implications for interactions with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered.</p><p>See section 4.5.</p><p>&nbsp;</p><p>Sucrose</p><p>This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucosegalactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p><p>&nbsp;</p><p>Interference with laboratory tests</p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, esomeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of esomeprazole on the pharmacokinetics of other drugs</u></p><p><u>Protease inhibitors</u></p><p>Omeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP2C19.</p><p>For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended. Co-administration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, Cmax and Cmin). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg qd) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg qd without omeprazole 20 mg qd. Co-administration of omeprazole (40 mg qd) reduced mean nelfinavir AUC, Cmax and Cmin by 36&ndash;39 % and mean AUC, Cmax and Cmin for the pharmacologically active metabolite M8 was reduced by 75-92%. Due to the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended (see section 4.4) and concomitant administration with esomeprazole and nelfinavir is contraindicated (see section 4.3).</p><p>For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg qd). Treatment with omeprazole 20 mg qd had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir). Treatment with esomeprazole 20 mg qd had no effect on the exposure of amprenavir (with and without concomitant ritonavir). Treatment with omeprazole 40 mg qd had no effect on the exposure of lopinavir (with concomitant ritonavir).</p><p><u>Methotrexate</u></p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p><u>Tacrolimus</u></p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.<em>&nbsp;</em></p><p>Medicinal products with pH dependent absorption</p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and Erlotinib can decrease and the absorption of digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should then be reinforced.</p><p>Medicinal products metabolised by CYP2C19</p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole-metabolising enzyme. Thus, when esomeprazole is combined with drugs metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. This should be considered especially when prescribing esomeprazole for on-demand therapy.</p><p><u>Diazepam</u></p><p>Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.</p><p><u>Phenytoin</u></p><p>Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.</p><p><u>Voriconazole</u></p><p>Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUC by 15% and 41%, respectively.</p><p><u>Cilostazol</u></p><p>Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p><u>Cisapride</u></p><p>In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life (t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole (see also section 4.4).</p><p><u>Warfarin</u></p><p>Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.</p><p><u>Clopidogrel</u></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/ pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o.daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40% and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.&nbsp;</p><p>When clopidogrel was given together with a fixed dose combination of esomeprazole 20 mg + ASA 81 mg compared to clopidogrel alone in a study in healthy subjects there was a decreased exposure by almost 40% of the active metabolite of clopidogrel. However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in the clopidogrel and the clopidogrel + the combined (esomeprazole + ASA) product groups.</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of esomeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution concomitant use of clopidogrel should be discouraged. <em><u>Investigated medicinal products with no clinically relevant interaction</u> </em></p><p><u>Amoxicillin and quinidine</u></p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.</p><p><u>Naproxen or rofecoxib</u></p><p>Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.</p><p>Effects of other medicinal products on the pharmacokinetics of esomeprazole</p><p><u>Medicinal products which inhibit CYP2C19 and/or CYP3A4</u></p><p>Esomeprazole is metabolised by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d.), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUC by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p>Medicinal products which induce CYP2C19 and/or CYP3A4</p><p>Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&#39;s wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p><p><strong>Paediatric population&nbsp;</strong></p><p>Interaction studies have only been performed in adults.<em> </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Clinical data on exposed pregnancies with Esomeprazole Magnesium Delayed Release Capsules are insufficient. With the racemic mixture omeprazole data on a larger number of exposed pregnancies stemmed from epidemiological studies indicate no malformative nor foetotoxic effects. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/foetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.</p><p>A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicates no malformative or foeto/neonatal toxicity of esomeprazole.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><u>Breast-feeding</u></p><p>It is not known whether esomeprazole is excreted in human breast milk. There is insufficient information on the effects of esomeprazole in newborns/infants. Esomeprazole should not be used during breast-feeding.</p><p><u>Fertility</u><br /><br />Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive and use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (rare) has been reported (see section 4.8). If affected patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p>Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post-marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose-related adverse reactions have been identified.</p><p>Tabulated list of adverse reactions</p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for esomeprazole and post-marketing. None was found to be dose-related. The reactions are classified according to frequency very common &ge;1/10; common &ge;1/100 to &lt;1/10; uncommon &ge;1/1,000 to &lt;1/100; rare &ge;1/10,000 to &lt;1/1,000; very rare &lt;1/10,000; not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Frequency</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Hypomagnesaemia (see section 4.4); severe hypomagnesaemia can correlate with hypocalcaemia. Hypomagnesaemia may also be associated with hypokalaemia.</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Aggression, hallucinations</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Taste disturbance</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td colspan="2" rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td colspan="2" style="vertical-align:top"><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic gland polyps</p><p>(benign)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Increased liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Alopecia, photosensitivity</p></td></tr><tr><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td colspan="2" style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td colspan="2" rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td colspan="2" style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Interstitial nephritis; in some patients renal failure has been reported concomitantly.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Rare</p></td><td colspan="2" style="vertical-align:top"><p>Malaise, increased sweating</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>Reporting of suspected adverse reactions&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&nbsp;&nbsp;&nbsp; not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull; </em></strong><strong>Saudi Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:512px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg were gastrointestinal symptoms and weakness. Single doses of 80 mg esomeprazole were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid-related disorders proton pump inhibitors</p><p>ATC code: A02B C05</p><p>Esomeprazole is the <em>S</em>-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the <em>R</em>- and <em>S</em>-isomer of omeprazole have similar pharmacodynamic activity.</p><p>Mechanism of action&nbsp;</p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H<sup>+</sup>K<sup>+</sup>-ATPase &ndash; the acid pump and inhibits both basal and stimulated acid secretion.</p><p>Pharmacodynamic effects&nbsp;</p><p>After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6&ndash;7 hours after dosing on day five.</p><p>After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GERD patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54% and 24%. Corresponding proportions for esomeprazole 40 mg were 97%, 92% and 56%.</p><p>Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown.&nbsp;</p><p>Healing of reflux esophagitis with esomeprazole 40 mg occurs in approximately 78% of patients after four weeks, and in 93% after eight weeks.</p><p>One week treatment with esomeprazole 20 mg b.i.d. and appropriate antibiotics, results in successful eradication of <em>H. pylori</em> in approximately 90% of patients.</p><p>After eradication treatment for one week, there is no need for subsequent monotherapy with antisecretory drugs for effective ulcer healing and symptom resolution in uncomplicated duodenal ulcers.&nbsp;</p><p>In a randomized, double blind, placebo-controlled clinical study, patients with endoscopically confirmed peptic ulcer bleeding characterised as Forrest Ia, Ib, IIa or IIb (9%, 43%, 38% and 10% respectively) were randomized to receive Esomeprazole Magnesium Delayed Release Capsules solution for infusion (n=375) or placebo (n=389). Following endoscopic hemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for 72 hours. After the initial 72 hour period, all patients received open-label 40 mg oral Esomeprazole Magnesium Delayed Release Capsules for 27 days for acid suppression. The occurrence of rebleeding within 3 days was 5.9% in the Esomeprazole Magnesium Delayed Release Capsules treated group compared to 10.3% for the placebo group. At 30 days post-treatment, the occurrence of rebleeding in the Esomeprazole Magnesium Delayed Release Capsules treated versus the placebo treated group 7.7% vs 13.6%.</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in both children and adults during long-term treatment with esomeprazole. The findings are considered to be of no clinical significance.</p><p>During long-term treatment with antisecretory drugs, gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as <em>Salmonella </em>and <em>Campylobacter</em> and, in hospitalised patients, possibly also <em>Clostridium difficile</em>.</p><p>Clinical efficacy&nbsp;</p><p>In two studies with ranitidine as an active comparator, Esomeprazole Magnesium Delayed Release Capsules showed better effect in healing of gastric ulcers in patients using NSAIDs, including COX-2 selective NSAIDs.</p><p>In two studies with placebo as comparator, Esomeprazole Magnesium Delayed Release Capsules showed better effect in the prevention of gastric and duodenal ulcers in patients using NSAIDs (aged &gt;60 and/or with previous ulcer), including COX-2 selective NSAIDs.</p><p>Paediatric population&nbsp;</p><p>In a study in paediatric GERD patients (&lt;1 to 17 years of age) receiving long-term PPI treatment, 61% of the children developed minor degrees of ECL cell hyperplasia with no known clinical significance and with no development of atrophic gastritis or carcinoid tumours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption&nbsp;</u></p><p>Esomeprazole is acid labile and is administered orally as enteric-coated granules. <em>In vivo</em> conversion to the <em>R</em>-isomer is negligible. Absorption of esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once daily administration. For 20 mg esomeprazole the corresponding values are 50% and 68% respectively.</p><p><strong>Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity. </strong></p><p><u>Distribution&nbsp;</u></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p><u>Biotransformation&nbsp;</u></p><p>Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p><u>Elimination&nbsp;</u></p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.&nbsp;</p><p>Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once daily dosing. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration.</p><p>The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.</p><p><u>Linearity/non-linearity&nbsp;</u></p><p>The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d. The area under the plasma concentration-time curve increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p><strong>Special patient populations&nbsp;</strong></p><p><u>Poor metabolisers </u>&nbsp;</p><p>Approximately 2.9 &plusmn;1.5% of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of esomeprazole.</p><p><u>Gender &nbsp;</u></p><p>Following a single dose of 40 mg esomeprazole the mean area under the plasma concentration-time curve is approximately 30% higher in females than in males. No gender difference is seen after repeated once daily administration. These findings have no implications for the posology of esomeprazole.</p><p><u>Hepatic impairment &nbsp;</u></p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction. Esomeprazole or its major metabolites do not show any tendency to accumulate with once daily dosing.</p><p><u>Renal impairment &nbsp;</u></p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p><p><u>Elderly &nbsp;</u></p><p>The metabolism of esomeprazole is not significantly changed in elderly subjects (71-80 years of age).</p><p><em><u>Paediatric population&nbsp;</u></em></p><p>Adolescents 12-18 years:</p><p>Following repeated dose administration of 20 mg and 40 mg esomeprazole, the total exposure (AUC) and the time to reach maximum plasma drug concentration (t<sub>max</sub>) in 12 to 18 year-olds was similar to that in adults for both esomeprazole doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:&nbsp;</p><p>Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sugar spheres, Hypromellose 2910, Meglumine, Poloxamer. Methyl Alcohol, Methylene chloride, Sodium lauryl sulphate, Isopropyl Alcohol, Methacrylic acid copolymer Triethyl citrate, Glyceryl monostearate, Talc, Sodium Hydroxide.</p><p>Empty hard gelatin capsule shells composition: FD &amp; C Blue1, D &amp; C Red 28, FD &amp; C Red 40 - D</p><p>&amp; C Yellow 10 Titanium dioxide<sub> </sub></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture.&nbsp;</p><p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;2 X 7&rsquo;s Alu-Alu-blister packs&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab  
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215
Manufacture: 
Hetero Lab Unit III, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>